Liminatus Pharma, Inc.
LIMN Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$2.89
KIRA · Stoqly’s AI analyst, in plain words
- Liminatus Pharma, Inc. lost $10.2M in fiscal 2025.
- Free cash flow was −$10.0M in fiscal 2025, — of revenue.
- Liminatus Pharma, Inc. owes $1.1M more than it holds in cash.
Market cap
$140M
P/E
—
Revenue
—
Net income
−$10.2M
Free cash flow
−$10.0M
Operating margin
—
Liminatus Pharma, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$10.2M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Liminatus Pharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Liminatus Pharma, Inc.
- CIK
- 0001971387
Liminatus Pharma, Inc. · LIMN
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Net income | −$3.5M | −$10.2M |
| Diluted EPS | −$0.20 | −$0.43 |
| Cash | ||
| Cash from operations | −$1.5M | −$10.0M |
| Capital expenditure | — | $0.0M |
| Free cash flow | — | −$10.0M |
| Share count change | — | 35.7% |
| Debt and strength | ||
| Cash and short-term investments | $0.0M | $0.3M |
| Debt incl. finance leases | $20.0M | $1.4M |
| Shareholders' equity | −$19.3M | −$9.8M |
| Current ratio | 0.2x | 0.0x |
| Interest coverage | −9.8x | −13.7x |
| Returns and quality | ||
| Return on capital | −415.7% | — |
| Piotroski F-score | — | 2 |
| Altman Z'' | −45.8 | −412.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Liminatus Pharma, Inc. · LIMN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.89 a share, the company is worth $140M.
Source: SEC EDGAR XBRL filings (CIK 0001971387). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.